Imugene's onCARlytics technology to feature in three abstracts at SITC 2022 - Kalkine Media

Highlights

• Imugene Limited’s onCARlytics to be featured in three abstracts at the SITC annual meeting
• The SITC 2022 meeting will be held from November 8 to 12 in Boston.
• onCARlytics is a CD19-expressing oncolytic virus which enters tumor cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies.

Imugene Limited (ASX:IMU), one of the eminent players in the biotech space, today revealed that its onCARlytics (CF33-CD19) oncolytic virus technology would be featured in three abstracts at the annual meeting of the Society for Immunotherapy of Cancer (SITC). The event is scheduled to be held from November 8-12 in Boston.

The SITC meeting is one of the most prestigious immunotherapy events on the calendar. This year, it will feature top-notch research presentations by various experts, oral and poster abstract presentations, many opportunities for networking, and discussions with members of the oncology community.

Abstract titles featuring Imugene's onCARlytics:
Title: Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors
Title: CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis® CD19 T cells results in significant tumor killing
Title: CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de novo CD19+ solid tumors

What is onCARlytics?

onCARlytics is a novel combination immunotherapy to eradicate solid tumours, which are otherwise difficult to treat with CAR T therapy alone. Using this technology, CD19-expressing oncolytic virus is released to enter tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies. The technology has been licensed exclusively by Imugene from City of Hope, one of the largest cancer research and treatment organisations in the US.

Image Source: Company Website

Imugene’s shares were trading at AU$0.190 each on 6 October 2022.